Background: In most cases of community-acquired pneumonia (CAP), an etiologic agent is not determined; the most common report from the microbiological evaluation of sputum cites “normal respiratory flora.” Non-diphtheria Corynebacterium spp., a component of this flora, is commonly viewed as a contaminant, but it may be the cause of pneumonia and the frequency with which it causes CAP may be underestimated.

Case presentations: This report presents 3 cases of CAP in which Corynebacterium spp. was clearly the predominant isolate; identification was confirmed by matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry. Two cases were caused by C. propinquum and one by C. striatum. Two patients had a tracheostomy and one was on hemodialysis. Patients who received an appropriate antibiotic responded well.

Conclusion: When identified as the predominant isolate in sputum from a patient with CAP, Corynebacterium spp. should be considered as a potential cause of the infection. In cases with patients who have compromised airway clearance or who are immunocompromised, microaspiration may be responsible. While some Corynebacterium spp. are susceptible to antibiotics usually prescribed for CAP, others are susceptible only to vancomycin or aminoglycosides. Vancomycin is thus the appropriate empiric antibiotic, pending speciation and susceptibility test results. The number of reported cases with result of antibiotic susceptibility testing, however, remains limited, and further investigation is needed. Non-diphtheria Corynebacterium spp. represent a noteworthy clinical cause of pneumonia. Identification by Gram stain and as a predominant organism on culture demands careful consideration for management.

Keywords: Pneumonia, Corynebacteria, Diphtheroids, Normal respiratory flora

Background

Pneumonia is an important cause of medical morbidity and mortality worldwide; pneumonia and influenza are listed as the 8th leading cause of death in the United States, with 57,062 deaths in 2015 [1]. Well-recognized and common causes of community-acquired pneumonia (CAP) in adults include bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus, and viruses such as influenza virus, respiratory syncytial virus, human metapneumovirus, and parainfluenza virus. Intensive recent investigations have failed to identify a causative organism in 50–62% of patients hospitalized for CAP [2, 3].

The most common laboratory report for sputum samples submitted for microbiological study is “mixed respiratory flora.” Pneumonia caused by S. pneumoniae is thought to result from unrecognized microaspiration of pneumococci that have colonized the nasopharynx [4]. The authors of the present study have previously hypothesized that unrecognized aspiration of less virulent bacteria that normally inhabit the nasopharynx might also cause pneumonia, especially in persons whose upper airways are bypassed or whose ability to clear aspirated organisms is damaged [5]. The present study examined the possibilities that: (i) careful examination of Gram-stained sputum and culture plates may reveal a predominant bacterium such as Corynebacterium spp. that are not generally regarded as a pulmonary pathogen; (ii) quantitative cultures may document a high concentration of these bacteria in sputum; and (iii) these organisms are in fact the cause of some cases of pneumonia.
Corynebacterium spp. Gram-positive bacilli that are often dismissed as contaminants have been reported to cause pneumonia (Table 1). New technologies, such as matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry enable rapid and precise identification of bacterial species [6], and highly sensitive techniques such as polymerase chain reaction (PCR) can help exclude a role for viruses, mycoplasma, and chlamydia. With the advent of these new technologies, there has been greater interest in Corynebacteria, and these organisms have been cited as emerging pathogens [7].

The present study reports on 3 well-documented cases of CAP due to Corynebacteria (2 cases of C. propinquum, 1 case of C. striatum) that were diagnosed in a 6-month period at a large tertiary care hospital. The study reviews the medical literature on Corynebacterium spp. as etiologic agents of pneumonia, with the goal of increasing awareness of the possibility that so-called “normal respiratory flora” may actually be responsible for an as-yet undetermined proportion of cases of CAP.

Case presentations
Case 1
A 75-year-old man on hemodialysis for end-stage renal disease was hospitalized for cough, fever, and altered mental status. His temperature was 103 °F, pulse 68, blood pressure 124/69, respiratory rate 22, and O2 saturation 96% on 2 L of O2 by nasal cannula. He was lethargic, with bibasilar crackles and a normal cardiac examination. His white blood cell (WBC) count was 20,100 cells/mm3 and his plasma procalcitonin was 1.1 ng/mL. Chest X-ray showed bibasilar infiltrates. Microscopic examination of Gram-stained sputum showed profuse polymorphonuclear leukocytes (PMNs) and Gram-positive rods, including those found within PMNs. Sputum yielded many Corynebacteria, identified by MALDI-TOF as C. propinquum, and few S. aureus. Sputum was liquefied with 2% N-acetyl cysteine and diluted serially; aliquots were cultured on blood agar and the number of colony forming units (CFU) was calculated [8]. The specimen contained 2×10⁹ CFU of Corynebacteria and <10⁵ CFU of S. aureus per mL. Blood cultures and viral PCR were negative. The patient was initially given vancomycin, cefepime, and ampicillin; treatment was switched to ampicillin/sulbactam after the Corynebacterium was reported susceptible. His mental status rapidly improved, and he was subsequently discharged to complete a 10-day course of amoxicillin/clavulanate.

Case 2
A 61-year-old man was found unresponsive post laryngectomy and tracheostomy for laryngeal squamous cell carcinoma. His temperature was 97.8 °F, pulse 99, blood pressure 114/86, and respiratory rate 22. Breath sounds were decreased bilaterally. WBC count was 7200 cells/mm³, lactate 1.2 mg/dL. Chest X-ray showed a new left-sided infiltrate. Sputum Gram stain revealed many Gram-positive rods, including those found within PMNs. Sputum yielded many Corynebacteria, identified by MALDI-TOF as C. propinquum, and few S. aureus. Sputum was liquefied with 2% N-acetyl cysteine and diluted serially; aliquots were cultured on blood agar and the number of colony forming units (CFU) was calculated [8]. The specimen contained 2×10⁹ CFU of Corynebacteria and <10⁵ CFU of S. aureus per mL. Blood cultures and viral PCR were negative. The patient was initially given vancomycin, cefepime, and ampicillin; treatment was switched to ampicillin/sulbactam after the Corynebacterium was reported susceptible. His mental status rapidly improved, and he was subsequently discharged to complete a 10-day course of linezolid.

Case 3
A 59-year-old male with widely metastatic squamous cell carcinoma of the tongue was admitted for bleeding from his tracheostomy site. His temperature was 99 °F, blood pressure 108/84, pulse 119, respiratory rate 24, and oxygen saturation 82% on room air. He had blood at the tracheostomy site and bibasilar rhonchi. WBC count was 22,000 cells/mm³, hemoglobin 11.1 g/dL, and lactate 1.8 mg/dL. Chest X-ray revealed a left upper-lobe infiltrate. Sputum sample showed profuse PMNs and Gram-positive rods. Culture yielded C. striatum (confirmed by MALDI-TOF) and few Escherichia coli. The patient was placed on comfort care and died 8 days later.

Discussion
Epidemiology
Non-diphtheria Corynebacterium spp.—commensal flora of the skin, respiratory tract, and mucous membranes [9, 10]—have been characterized as emerging pathogens [7]. Among reported cases, infections of the respiratory tract are second in frequency only to those of the urinary tract [11]. The literature search revealed 67 reported cases of pulmonary infection due to non-diphtheria Corynebacterium spp., summarized in Table 1. Cases include pneumonia (community-acquired, hospital-acquired, or ventilator-associated), necrotizing pneumonia, and empyema, although pneumonia predominated. Implicated Corynebacterium spp. include C. pseudodiphtheriticum [12, 13], C. propinquum [14], C. striatum [14–18], C. afermentans [19], C. xerosis [20], C. jeikeium [10, 21–23], C. pseudotuberculosis [24, 25], C. mucifaciens [26], C. ulcerans [27], and C. macginleyi [28].
Table 1: Previously documented cases of *Corynebacterium* pulmonary infection

| Organism isolated          | No. of cases | Age/Sex | Co-morbid conditions                                                                 | Diagnosis                               | Methods of Diagnosis                                                                 | Mortality |
|---------------------------|--------------|---------|-------------------------------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------|-----------|
| *C. accolens* [46]        | 1            | 72F     | DM, myocardial infarction, triple aortic bypass, heart failure                       | Pneumonia                               | Bronchoalveolar brush sample. Culture also yielded small numbers of *P. aeruginosa*     | 1 (100%)  |
| *C. aerofaciens* [19]     | 1            | 27F     | HIV                                                                                 | Empyema                                 | Pleural fluid and blood culture positive. Sputum culture reported “normal respiratory flora” | 0 (0%)    |
| *C. jeikeium* [10, 22, 23, 47] | 5            | 48F, 28F, 29F, 76M, 77F | 2 Acute myelogenous leukemia, 1 Hodgkin’s lymphoma and Acute myelomonocytic leukemia, 1 old pulmonary-tuberculosis, and 1 COPD | Pneumonia, (necrosis and hemorrhage in 1 case) | Positive gram stain and culture from 1 post-mortem pneumonia; 4 positive respiratory cultures (including 1 TTA). In 1 case, sputum yielded $10^7$ *C. jeikeium*, $>10^7$ *S. aureus* and $10^7$ *P. aeruginosa* per ml. TTA culture yielded $>10^5$ *C. jeikeium*, *10^5* *P. aeruginosa*, and $10^7$ *S. aureus*; FNA yielded pure growth of *C. jeikeium* | 4 (80%)   |
| *C. macginleyi* [28]      | 1            | 73F     | Metastatic lung adenocarcinoma, chemotherapy, intubated post-bronchoscopy            | Ventilator-associated pneumonia         | Sputum culture had $10^5$ CFU/mL *C. macginleyi*                                         | 0 (0%)    |
| *C. macrificiens* [26]    | 1            | 51M     | DM                                                                                 | Cavity pneumonia                        | Not described                                                                            | 0 (0%)    |
| *C. propinquum* [14, 48]  | 4            | 72F, 79M, 83M, 7F | 2 DM, 1 non-Hodgkin’s MALT lymphoma, 2 Rheumatoid arthritis, 2 COPD, 1 ataxia telangiectasia on inhaled corticosteroids | Pneumonia                               | 3 sputum culture; 1 case with bronchial aspirate and bronchoalveolar lavage yielding only *C. propinquum* and blood culture positive for *S. pneumonia* | 0 (0%)    |
| *C. pseudo-diphtheriticum* [12–14, 33–38, 49–55] | 40           | 91F, 40M, 29F, 70 M, 71M, 68M, 72M, 79F, 76F, 83M, 75M, 68M, 78M, 65M, 64M, 67M, 62M, 66M, 50F, 27F, 69F, 29M, 47M, 41M, 24M, 43M, 34M, 33M, 33M, 43M, 34M, 29M, 30M, 80F, 9F, 59M, 46M, 75M | 2 CKD, 3 CHF, 10 COPD, 4 DM, 2 asthma, SLE, 1 Adult T-cell lymphoproliferative virus, 1 tracheostomy, 3 lung cancers, 1 epidemoid carcinoma, 2 autoimmune disorder on steroid therapy, 2 infections, 1 amyotrophic lateral sclerosis, 10 HIV/AIDS, 3 previous tuberculosis, 2 recent Pneumocystis jiroveci pneumonia, 1 cystic fibrosis | Pneumonia | 15 sputum Gram stains, 2 bronchial secretions, 1 bronchial wash; Cultures also yielded fewer numbers of other bacteria: *S. aureus* (2), *H. influenzae* (1), *S. pneumoniae* (3), *S. maltophilia* (1), *P. aeruginosa* (1), *E. cloaca* (1) | 4 (10%); 9 status unknown, 27 resolved |
| *C. pseudotuberculosis* [24, 25] | 2            | 23F, 28M | 2 veterinary students (1 known exposure to sick horses)                             | Pneumonia                               | TTA or CT guided transbronchial biopsy                                                   | 0 (0%)    |
| *C. striatum* [14–17, 56–58] | 7            | 68F, 47F, 28F, 27M, 69M, 58M, 69F | 1 DM, 2 HIV/AIDS, 1 alcohol use, 1 COPD, 1 heart transplant, 1 RA on prednisone | Pneumonia                               | 2 sputum, 2 BAL cultures ($4 \times 10^7$ CFU/mL and > $10^4$ CFU/mL), 1 bronchoscopy brush sample, 1 empyema, 1 pleural fluid +1 lung tissue culture | 1 (14%)   |
| *C. ulcerans* [27, 59]    | 2            | 78M, 80F | 1 Metastatic squamous cell carcinoma of the lung, 1 HTN                             | Pneumonia                               | 2 positive sputum cultures, 1 confirmed by BAL                                          | 2 (100%)  |
| *C. xerosis* [60]         | 1            | 72M     | CHF, COPD                                                                           | Pneumonia                               | Transtracheal aspiration                                                                 | 0 (0%)    |
| *C. xerosis* [20]         | 1            | 63M     | AML                                                                                 | Pneumonia                               | BAL culture yielded $10^5$ *C. xerosis* /ml                                              | 1 (100%)  |

**Note:** DM Diabetes Mellitus, HTN Hypertension, HLD Hyperlipidemia, HIV Human Immunodeficiency Virus, CFU colony forming units, COPD Chronic Obstructive Pulmonary Disease, RML Right middle lobe of lung, TTA transtracheal aspiration, FNA Fine Needle Aspiration, cx culture, MALT Mycobacterium-associated lymphoid tissue, CKD Chronic kidney disease, CHF Congestive heart failure, SLE Systemic Lupus Erythematosus, AIDS Acquired Immunodeficiency Syndrome, RA Rheumatoid arthritis, BAL bronchoalveolar lavage
Microbiology, pathogenesis, and immunity

“Coryneform bacteria” is the umbrella term for the class of bacteria comprised of facultative intracellular, non-spore-forming, catalase-positive, non-acid-fast, non-motile, and irregularly-shaped Gram-positive rods [29]. Based on 16S rRNA sequencing studies, Corynebacterium belongs to a subdivision of Gram-positive eubacteria with high guanine-to-cytosine content, which also contains Arthrobacter, Mycobacterium, Nocardia, and Streptomyces [30]. Coryneform bacteria are pleomorphic throughout their life cycle, and may have thickenings at either end, giving the “coryneform” name, meaning “club-shaped”; they may be clustered, forming shapes that resemble a “V,” “palisades,” or “Chinese letters” [29]. Because of their relation to C. diphtheriae, their common name is “diphtheroids.”

Little is known about the virulence factors of the non-diphtheria Corynebacterium spp. that may contribute to CAP and other infections [31]. C. pseudodiphtheriticum, the species most commonly implicated as a cause of pneumonia, has an ability to invade human epithelial type 2 (HEP-2) cells and survive for 24 h after infection, suggesting a potential mechanism to escape killing by the innate immune system [31]. Invasive strains form biofilms and bind fibrinogen and fibronectin, which may be facilitated by fimbrial subunits [31, 32].

Predisposing conditions

With the exception of 2 cases of pneumonia due to C. pseudotuberculosis in veterinary workers [24, 25], all other reported cases of Corynecbacterial pneumonia have occurred in persons whose upper airways are bypassed, whose ability to clear aspirated organisms is damaged, or who have immunocompromising conditions (Table 2). The great majority of patients have had conditions that affect pulmonary clearance, including chronic obstructive pulmonary disease (COPD), cystic fibrosis [33], and previous radiotherapy to the thorax [27]. Some have had procedures that bypass protective mechanisms of the upper airways such as recent endotracheal intubation [28, 34, 35] or laryngectomy [36], as seen in Cases 2 and 3 in the present study. Among patients who are immunocompromised, co-morbidities included HIV infection [17, 37, 38], chemotherapy [10, 28], hematologic malignancies or conditions that compromise PMN function such as diabetes mellitus, alcohol use disorder [16] or end-stage renal disease, as seen in Case 1 in the present study.

Clinical description

The presentation of pneumonia due to Corynebacteria does not differ from that due to bacterial pneumonia of any other cause: cough, fever, and altered mental status are usually present, as observed in the present study’s 3 cases. Cases of community-acquired or ventilator-associated pneumonia, cavitary pneumonia, empyema, and bacteremia have been described (Table 1). Only 5 (7.5%) of the 67 reported patients with Corynebacterial pneumonia have been bacteremic with Corynebacteria. This suggests that blood cultures may be of minimal utility for confirming any sputum findings. Pneumonia caused by the quintessential pulmonary pathogen, S. pneumoniae, is bacteremic in no more than approximately 25% of cases [39], and the rate of bacteremia is far lower in pneumonia due to less pathogenic organisms, such as nontypable H. influenzae [40] or Moraxella catarrhalis [41].
Table 2 Risk factors in reported cases of Corynebacterial pneumonia

| Risk Category                  | Examples                                               |
|-------------------------------|--------------------------------------------------------|
| Decreased clearance / Damaged lung structure | Chronic obstructive pulmonary disease  
Previous radiation to thorax  
Cystic fibrosis  
Heavy smoking history |
| Bypass of airway protection   | Active or recent endotracheal intubation  
Laryngectomy |
| Immunodeficiency              | Human immunodeficiency virus (HIV) infection  
Ongoing or recent cancer chemotherapy  
Conditions that compromise function of PMNs (e.g. poorly controlled diabetes mellitus, end-stage renal disease)  
Steroid use secondary to autoimmune disease  
Immunosuppressive drug use secondary to transplant |
| Miscellaneous factors        | Alcohol use disorder                                    |
| Environmental                | Exposure to sick animals (C. pseudotuberculosis only)   |

Laboratory diagnosis
Given the limited utility of blood cultures in diagnosing Corynebacterial pneumonia, diagnosis requires a multifaceted approach. In most previous case reports, diagnosis has been based on microscopic examination of a Gram-stained sputum and careful examination of culture plates [42]. In the 3 cases discussed in this report, the sputum Gram stain showed profuse numbers of Corynebacteria. In 12 of the previously reported cases, quantitative studies were carried out on sputum, bronchoalveolar lavage samples, or protected bronchial brush samples (Table 1) with few or no colonies of other potentially pathogenic bacteria, as in Case 2 in which quantitative sputum culture revealed \(1.2 \times 10^9\) CFU/mL. Pneumonia due to Corynebacteria may occur far more commonly than has been reported, because the finding of these organisms is usually dismissed as “normal mouth flora” or “normal respiratory flora.”

MALDI-TOF is useful in providing precise speciation, as was employed in the 3 cases discussed in this report. An analysis of 83 Corynebacterial samples compared MALDI-TOF with API Coryne V2.0 (bioMérieux, Marcy l’Etoile, France), which is the method that has been most widely used to speciate Corynebacteria in the past few decades. Identification matched in 73 of 83 (88%) samples [43]. 16S rRNA sequencing was used to resolve the discrepancy in the remaining 10 samples. All 10 matched with MALDI-TOF’s identification, which demonstrates the superiority of this methodology [43, 44].

Management
Corynebacterium spp. that have been identified as causes of pneumonia or empyema are delineated in Table 1. C. pseudodiptheriticum, the cause of about two-thirds of reported Corynebacterial pneumonia cases, is susceptible to penicillin, cephalosporins, and vancomycin, but resistant to macrolides, clindamycin, trimethoprim/sulfamethoxazole, quinolones, and/or rifampin (Table 3). Some species, including C. jeikeium, C. macginleyi, and C. xerosis, are resistant to all common antibiotics except glycopeptides such as vancomycin (Table 3). Intermediately resistant organisms such as C. propinquum and C. striatum, implicated in the present study’s 3 cases, are also consistently susceptible to vancomycin and ampicillin, but variably susceptible to penicillin and cephalosporins, and commonly resistant to macrolides, clindamycin, trimethoprim-sulfamethoxazole, fluoroquinolines, and rifampin. The other reported Corynebacterium spp.—C. accolens, C. afermentans, C. mucificiens, C. pseudotuberculosis, C. urealyticum, and C. ulcerans—had only 1–2 case reports each, and/or did not include comprehensive susceptibility reports. These cases are summarized in Table 3. Although only one pneumonia case report [17] included susceptibility to linezolid or tigecycline, a prospective study analyzing infections due to Corynebacteria from a variety of sites revealed that all isolates—the majority being C. amycolatum, C. accolens, C. minutissimum, and C. glucuronolyticum (strains that are not regularly implicated in pneumonia)—were susceptible to linezolid and tigecycline [45].

These results suggest that, when a Gram-stained sputum from a patient with pneumonia reveals Corynebacteria as the predominant isolate, vancomycin should be the initial antibiotic of choice. If MALDI-TOF identifies a species that is likely to be susceptible to other antibiotics, the empiric antibiotic of choice can be revised, or definitive antibiotic treatment can be given based on results of antibiotic susceptibility testing as determined by gradient diffusion strip testing. There is no accepted recommendation for length of treatment for Corynebacterial pneumonia. However, among case reports, treatment time has ranged from 10 days for a case of C. macginleyi pneumonia [28], to 8 weeks for a cavitating pneumonia due to C. jeikeium [22], to 14 months for pneumonia due to C. pseudotuberculosis [25]. It seems reasonable to select a duration of treatment based on the nature of the lung lesion. Infiltrates should respond...
to the same 7 days of treatment that are used for other bacterial pneumonias, whereas cavitating pneumonia should be treated for longer periods, perhaps until the cavity is closed. In some cases, inadequate responses have been observed in cases of a lung abscess or cavitation, prompting surgical resection [16, 37].

Conclusions

Although traditionally regarded as part of normal respiratory flora, Corynebacteria has the capacity to cause pneumonia in immunocompromised patients, or in immunocompetent patients who have impaired airway clearance and/or structural damage to the airways. The presentation is similar to that of any other bacterial pneumonia. Such infections may be far more common than has been previously suggested, because the finding of Corynebacteria on Gram stain and culture is likely to lead to a report of “mixed” or “normal respiratory flora.” A correct diagnosis can be made primarily by visualization of large numbers of diphtheroids in microscopic fields that contain > 20 WBC per epithelial cell, especially if the bacteria are located within PMNs, and supported by a culture in which the overwhelmingly predominant organism is Corynebacteria.

Table 3 Antibiotic susceptibilities of Corynebacterium spp. identified as causes of pulmonary infection

| Organism                  | Antibiotic | PCN | AMX | AMC | AMP | CEF | CFZ | CXM | CRO | CTX | SXT | ERY | AZM | CLI | CIP |
|---------------------------|------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| C. accolens (n = 1)       |            | 100 | 100 |     |     |     |     |     |     |     |     |     |     |     |     |
| C. afermentans (n = 1)    |            |     |     |     |     |     |     |     |     | 100 |     |     |     |     |     |
| C. jeikeium (n = 5)       |            |     |     |     |     |     |     |     |     | 100 |     |     |     |     |     |
| C. macginleyi (n = 1)     |            |     |     |     |     |     |     |     |     | 100 |     |     |     |     |     |
| C. mucificiens (n = 1)    |            | 100 | 100 |     |     |     |     |     |     |     |     |     |     |     |     |
| C. propinquum (n = 1)     |            |     |     |     |     |     |     |     |     | 100 |     |     |     |     |     |
| C. pseudodiphtheriticum (n = 24) |           | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |     |
| C. pseudotuberculosis (n = 2) |            | 100 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| C. striatum (n = 7)       |            |     |     |     |     |     |     |     |     |     |     |     |     |     | 75  |
| C. ulcerans (n = 2)       |            |     |     |     |     |     |     |     |     |     |     |     |     |     | 50  |
| C. urealyticum (n = 1)    |            | 100 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| C. xerosis (n = 1)        |            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|                           |            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

Antibiotic susceptibility for each Corynebacterium spp. as reported in all previous cases of Corynebacterial pneumonia (see Table 1 for reference listing) was calculated from number of sensitive isolates as a percentage of the total number of isolates tested with that antibiotic. Blank boxes represent a lack of testing information. The total number of isolates of each species is provided (n). Not all isolates under each organism were tested for the same antibiotics.

PCN penicillin, AMX amoxicillin, AMC amoxicillin-clavulanic acid, AMP ampicillin, CEF cefalothin, CFZ cefazolin, CXM cefuroxime, FOX cefoxitin, CRO ceftriaxone, CTX cefotaxime, OFX ofloxacin, SXT trimethoprim-sulfamethoxazole, ERY erythromycin, AZM azithromycin, CLI clindamycin, LCM lincomycin, RIF rifampin, GEN gentamicin, TOB tobramycin, VAN vancomycin, LID linezolid, IPM Imipenem, AMK amikacin, DOX doxycycline, TET tetracycline, TEC teicoplanin, CHL chloramphenicol, FOF Fosfomycin, DAP daptomycin.

to the same 7 days of treatment that are used for other bacterial pneumonias, whereas cavitating pneumonia should be treated for longer periods, perhaps until the cavity is closed. In some cases, inadequate responses have been observed in cases of a lung abscess or cavi-
The authors declare that they have no competing interests.

Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
KY tabulated previous literature. KY and DMM drafted the manuscript. All authors contributed to the design of the study and the writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Approval by the Institutional Review Board, Baylor College of Medicine. The protocol permits the study of patients admitted to the Michael E. DeBakey VA Medical Center with community acquired pneumonia for the purpose of reviewing etiology and appropriateness of treatment. The only image we show is a Gram stain of sputum which is a discarded sample. The cases that are reported have none of the 18 known patient identifiers.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 27 April 2018 Accepted: 18 September 2018
Published online: 05 October 2018

References
1. National Center for Health Statistics. Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville, MD. 2017.
2. Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Inf Secur. 2013;67:11–8.
3. Jain S, Self WH, Wunderink RG, Team CES. Community-acquired pneumonia requiring hospitalization. N Engl J Med. 2015;373:2362.
4. Janoff BM, Musher DM. Streptococcus pneumoniae. In: Bennett JDR, Blaser MJ, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Saunders; 2015. p. 2310–27.
5. Musher DM, Abers MS, Bartlett JG. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis. 2017;65:1736–44.
6. Sloan A, Wang G, Cheng K. Traditional approaches versus mass spectrometry in bacterial identification and typing. Clin Chim Acta. 2017;473:180–5.
7. Harrington AT, Claridge III LE, Mahlen SD. Chapter 91 - Corynebacterium spp. as established and emerging respiratory pathogens A2 - Tang, Yi-Wei. In: Sussman M, Liu D, Poxton I, Schwartzman J, editors. Molecular Medical Microbiology. 2nd ed. Boston: Academic Press; 2015. p. 1627–33.
8. Thorsteinsson SB, Musher DM, Fagan T. The diagnostic value of sputum culture in acute pneumonia. JAMA. 1975;233:894–5.
9. von Graevenitz A, Punter-Streit V, Riegel P, Funke G. Coryneform bacteria in throat cultures of healthy individuals. J Clin Microbiol. 1998;36:2087–8.
10. Water FJ. Pathology of culture-proven JK Corynebacterium pneumonia. An autopsy case report. Am J Clin Pathol. 1989;91:616–9.
11. Camello TC, Souza MC, Martins CA, et al. Corynebacterium pseudodiphteriticum isolated from relevant clinical sites of infection: a human pathogen overlooked in emerging countries. Lett Appl Microbiol. 2009;48:458–64.
38. Roig P, Lopez MM, Arriero JM, et al. Corynebacterium pseudodiphtheriticum pneumonia in a patient diagnosed with HIV infection. An Med Interna. 1993;10:499–500.

39. Heffron R. Pneumonia with special reference to pneumococcus lobar pneumonia. New York: The Commonwealth Fund; 1939.

40. Musher DM, Kubitschek KR, Crennan J, Baughn RE. Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae. Ann Intern Med. 1983;99:444–50.

41. Wallace RJ Jr, Musher DM. In honor of Dr. Sarah Branham, a star is born. The realization of Branhamella catarrhalis as a respiratory pathogen. Chest. 1986;90:447–50.

42. Coyle MB, Lipsky BA. Coryneform bacteria in infectious diseases: clinical and laboratory aspects. Clin Microbiol Rev. 1990;3:227–46.

43. Vila J, Juiz P, Salas C, et al. Identification of clinically relevant Corynebacterium spp., Arcanobacterium haemolyticum, and Rhodococcus equi by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2012;50:1745–7.

44. Bao R, Gao X, Hu B, Zhou Z. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for identification of Corynebacterium species. J Thorac Dis. 2017;9:3239–45.

45. Reddy BS, Chaudhury A, Kalawat U, et al. Isolation, speciation, and antibiogram of clinically relevant non-diphtherial Corynebacteria (Diphtheroids). Indian J Med Microbiol. 2012;30:52–7.

46. Losada I, Daza RM, Merino J, et al. Corynebacterium CDC G1: pathogen or colonizer? Enferm Infecc Microbiol Clin. 1996;14:510–1.

47. Riebel W, Frantz N, Adelstein D, Spagnuolo PJ. Corynebacterium JK: a cause of nosocomial device-related infection. Rev Infect Dis. 1986;8:42–9.

48. Malkocoglu G, Gencer H, Kaya A, et al. Corynebacterium propinquum bronchopneumonia in a child with ataxia telangiectasia. Turk J Pediatr. 2016;58:558–61.

49. Furiasse D, Garparotto AM, Monterisi A, et al. Pneumonia caused by Corynebacterium pseudodiphtheriticum. Rev Argent Microbiol. 2016;48:290–2.

50. Chudnicka A, Szmygin-Milanowska K, Kieszko R, et al. The role of opportunistic species of Corynebacterium pseudodiphtheriticum in the pathogenesis of CAP (community acquired pneumonia). Ann Univ Mariae Curie-Skłodowska. Med. 2003;58:142–8.

51. Cohen Y, Force G, Gros I, et al. Corynebacterium pseudodiphtheriticum pulmonary infection in AIDS patients. Lancet. 1992;340:145–5.

52. Donaghy M, Cohen J. Pulmonary infection with Corynebacterium hofmannii complicating systemic lupus erythematosus. J Infect Dis. 1983;147:962.

53. Nishiyama A, Ishida T, Ito A, Arita M. Bronchopneumonia caused by Corynebacterium pseudodiphtheriticum. Intern Med. 2013;52:1847.

54. Cowling P, Hall L. Corynebacterium striatum: a clinically significant isolate from sputum in chronic obstructive airways disease. J Inf Secur. 1993;26:335–6.

55. Tarr PE, Stock F, Cooke RH, et al. Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient. Transpl Infect Dis. 2003;5:53–8.

56. Vermes R, Krawitz GR. Corynebacterium striatum empyema and osteomyelitis in a patient with advanced rheumatoid arthritis. BMJ Case Rep. 2016; https://doi.org/10.1136/bcr-2016-214691.

57. Jacobs NF, Jr, Perilin CA. “Diphtheroid” pneumonia. South Med J. 1979;72:475–6.

58. Nazerni MW, Musher DM. Empyema due to aerobic diphtheroids following dental extraction. Am Rev Respir Dis. 1973;108:1221–3.